HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies
Tóm tắt
Từ khóa
Tài liệu tham khảo
2006, ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death, Circulation, 114, e385, 10.1161/CIRCULATIONAHA.106.178233
Liebman, 2001, Some legal, social, and ethical issues related to the genetic testing revolution, as exemplified in the long QT syndrome, J Electrocardiol, 34, 183, 10.1054/jelc.2001.28866
Nelson, 2001, (Committee on Bioethics), Pediatrics, 107, 1451
Hendriks, 2008, Familial disease with a risk on sudden death: a longitudinal study of the psychological consequences of predictive testing for Long QT syndrome, Heart Rhythm, 5, 719, 10.1016/j.hrthm.2008.01.032
Christiaans, 2009, Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: a cross-sectional cohort study, Am J Med Genet, 149A, 602, 10.1002/ajmg.a.32710
Tester, 2011, Genetic testing for potentially lethal, highly treatable inherited cardiomyopathies/channelopathies in clinical practice, Circulation, 123, 1021, 10.1161/CIRCULATIONAHA.109.914838
Napolitano, 2005, Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice, Jama, 294, 2975, 10.1001/jama.294.23.2975
Hofman, 2010, Active cascade screening in primary inherited arrhythmia syndromes: does it lead to prophylactic treatment?, J Am Coll Cardiol, 55, 2570, 10.1016/j.jacc.2009.12.063
Ackerman, 2003, Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome, Mayo Clin Proc, 78, 1479, 10.4065/78.12.1479
Ackerman, 2004, Spectrum and prevalence of cardiac sodium channel variants among Black, White, Asian, Hispanic individuals: implications for arrhythmogenic susceptibility and Brugada/Long QT syndrome genetic testing, Heart Rhythm, 1, 600, 10.1016/j.hrthm.2004.07.013
Kapa, 2009, Genetic testing for long QT syndrome—distinguishing pathogenic mutations from benign variants, Circulation, 120, 1752, 10.1161/CIRCULATIONAHA.109.863076
Kapplinger, 2011, Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated mutations from background genetic noise, J Am Coll Cardiol, 57, 2317, 10.1016/j.jacc.2010.12.036
Ackerman, 2008, Congenital long QT syndrome in electrical diseases of the heart; genetics mechanisms, treatment, prevention, 462
Priori, 1999, Low penetrance in the long-QT syndrome: clinical impact, Circulation, 99, 529, 10.1161/01.CIR.99.4.529
Tester, 2006, Effect of clinical phenotype on yield of long QT syndrome genetic testing, J Am Coll Cardiol, 47, 764, 10.1016/j.jacc.2005.09.056
Vincent, 1992, The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome, N Engl J Med, 327, 846, 10.1056/NEJM199209173271204
Priori, 2003, Risk stratification in the long-QT syndrome, N Engl J Med, 348, 1866, 10.1056/NEJMoa022147
Vyas, 2006, Epinephrine QT stress testing in the evaluation of congenital long-QT syndrome: diagnostic accuracy of the paradoxical QT response, Circulation, 113, 1385, 10.1161/CIRCULATIONAHA.105.600445
Takenaka, 2003, Exercise stress test amplifies genotype-phenotype correlation in the LQT1 and LQT2 forms of the long-QT syndrome, Circulation, 107, 838, 10.1161/01.CIR.0000048142.85076.A2
Shimizu, 2004, Diagnostic value of epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congenital long QT syndrome, Heart Rhythm, 1, 276, 10.1016/j.hrthm.2004.04.021
Krahn, 2005, Diagnosis of unexplained cardiac arrest: role of adrenaline and procainamide infusion, Circulation, 112, 2228, 10.1161/CIRCULATIONAHA.105.552166
Viskin, 2010, The response of the QT interval to the brief tachycardia provoked by standing: a bedside test for diagnosing long QT syndrome, J Am Coll Cardiol, 55, 1955, 10.1016/j.jacc.2009.12.015
Schwartz, 1993, Diagnostic criteria for the long QT syndrome, Circulation, 88, 782, 10.1161/01.CIR.88.2.782
Schwartz, 2009, Prevalence of the congenital long-QT syndrome, Circulation, 120, 1761, 10.1161/CIRCULATIONAHA.109.863209
Goldenberg, 2008, Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome, Circulation, 117, 2184, 10.1161/CIRCULATIONAHA.107.701243
Hobbs, 2006, Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome, Jama, 296, 1249, 10.1001/jama.296.10.1249
Monnig, 2006, Electrocardiographic risk stratification in families with congenital long QT syndrome, Eur Heart J, 27, 2074, 10.1093/eurheartj/ehl159
Jons, 2010, Risk of fatal arrhythmic events in long QT syndrome patients after syncope, J Am Coll Cardiol, 55, 783, 10.1016/j.jacc.2009.11.042
Wang, 1995, SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome, Cell, 80, 805, 10.1016/0092-8674(95)90359-3
Schwartz, 1985, Idiopathic long QT syndrome: progress and questions, Am Heart J, 109, 399, 10.1016/0002-8703(85)90626-X
Curran, 1995, A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome, Cell, 80, 795, 10.1016/0092-8674(95)90358-5
Wang, 1996, Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias, Nat Genet, 12, 17, 10.1038/ng0196-17
Abbott, 1999, MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia, Cell, 97, 175, 10.1016/S0092-8674(00)80728-X
Plaster, 2001, Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome, Cell, 105, 511, 10.1016/S0092-8674(01)00342-7
Splawski, 2004, Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism, Cell, 119, 19, 10.1016/j.cell.2004.09.011
Vatta, 2006, Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome, Circulation, 114, 2104, 10.1161/CIRCULATIONAHA.106.635268
Medeiros-Domingo, 2007, SCN4B-encoded sodium channel beta4 subunit in congenital long-QT syndrome, Circulation, 116, 134, 10.1161/CIRCULATIONAHA.106.659086
Ueda, 2008, Syntrophin mutation associated with long QT syndrome through activation of the nNOS-SCN5A macromolecular complex, Proc Natl Acad Sci U S A, 105, 9355, 10.1073/pnas.0801294105
Yang, 2010, Identification of a Kir3.4 mutation in congenital long QT syndrome, Am J Hum Genet, 86, 872, 10.1016/j.ajhg.2010.04.017
Priori, 1999, Genetic and molecular basis of cardiac arrhythmias: impact on clinical management part III, Circulation, 99, 674, 10.1161/01.CIR.99.5.674
Eddy, 2008, Identification of large gene deletions and duplications in KCNQ1 and KCNH2 in patients with long QT syndrome, Heart Rhythm, 5, 1275, 10.1016/j.hrthm.2008.05.033
Tester DJ, Benton AJ, Train L, et al. Prevalence and spectrum of large deletions or duplications in the major long QT syndrome-susceptibility genes and implications for long QT syndrome genetic testing. Am J Cardiol;106:1124–1128.
Goldenberg, 2006, Clinical course and risk stratification of patients affected with the Jervell and Lange-Nielsen syndrome, J Cardiovasc Electrophysiol, 17, 1161, 10.1111/j.1540-8167.2006.00587.x
Schwartz, 2006, The Jervell and Lange-Nielsen syndrome, Circulation, 113, 783, 10.1161/CIRCULATIONAHA.105.592899
Kapplinger, 2009, Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test, Heart Rhythm, 6, 1297, 10.1016/j.hrthm.2009.05.021
Schwartz, 2006, The congenital long QT syndromes from genotype to phenotype: clinical implications, J Intern Med, 259, 39, 10.1111/j.1365-2796.2005.01583.x
Taggart, 2007, Diagnostic miscues in congenital long-QT syndrome, Circulation, 115, 2613, 10.1161/CIRCULATIONAHA.106.661082
Napolitano, 2005, Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice, Jama, 294, 2975, 10.1001/jama.294.23.2975
Tester, 2005, Spectrum and prevalence of cardiac ryanodine receptor (RyR2) mutations in a cohort of unrelated patients referred explicitly for long QT syndrome genetic testing, Heart Rhythm, 2, 1099, 10.1016/j.hrthm.2005.07.012
Kapa, 2009, Genetic testing for long-QT syndrome: distinguishing pathogenic mutations from benign variants, Circulation, 120, 1752, 10.1161/CIRCULATIONAHA.109.863076
Rautaharju, 2009, AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval, J Am Coll Cardiol, 53, 982, 10.1016/j.jacc.2008.12.014
Schwartz, 2010, Repolarization abnormalities in the newborn, J Cardiovasc Pharmacol, 55, 539, 10.1097/FJC.0b013e3181d86525
Yang, 2002, Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes, Circulation, 105, 1943, 10.1161/01.CIR.0000014448.19052.4C
Paulussen, 2004, Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients, J Mol Med, 82, 182, 10.1007/s00109-003-0522-z
Lehtonen, 2007, Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes, Heart Rhythm, 4, 603, 10.1016/j.hrthm.2007.01.019
Zhang, 2000, Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes, Circulation, 102, 2849, 10.1161/01.CIR.102.23.2849
Schwartz, 2001, Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias, Circulation, 103, 89, 10.1161/01.CIR.103.1.89
Choi, 2004, Spectrum and frequency of cardiac channel defects in swimming-triggered arrhythmia syndromes, Circulation, 110, 2119, 10.1161/01.CIR.0000144471.98080.CA
Moss, 2007, Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene, Circulation, 115, 2481, 10.1161/CIRCULATIONAHA.106.665406
Shimizu, 2009, Genotype-phenotype aspects of type 2 long QT syndrome, J Am Coll Cardiol, 54, 2052, 10.1016/j.jacc.2009.08.028
Crotti, 2007, The common long-QT syndrome mutation KCNQ1/A341V causes unusually severe clinical manifestations in patients with different ethnic backgrounds: toward a mutation-specific risk stratification, Circulation, 116, 2366, 10.1161/CIRCULATIONAHA.107.726950
Makita, 2008, The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome, J Clin Invest, 118, 2219
Villain, 2004, Low incidence of cardiac events with beta-blocking therapy in children with long QT syndrome, Eur Heart J, 25, 1405, 10.1016/j.ehj.2004.06.016
Monnig, 2005, Implantable cardioverter-defibrillator therapy in patients with congenital long-QT syndrome: a long-term follow-up, Heart Rhythm, 2, 497, 10.1016/j.hrthm.2005.02.008
Schwartz, 2010, Who are the long-QT syndrome patients who receive an implantable cardioverter-defibrillator and what happens to them?, Circulation, 122, 1272, 10.1161/CIRCULATIONAHA.110.950147
Horner, 2010, Implantable cardioverter defibrillator therapy for congenital long QT syndrome: a single-center experience, Heart Rhythm, 7, 1616, 10.1016/j.hrthm.2010.08.023
Moss, 2000, Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome, Circulation, 101, 616, 10.1161/01.CIR.101.6.616
Schwartz, 1995, Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate, Circulation, 92, 3381, 10.1161/01.CIR.92.12.3381
Ruan, 2007, Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients, Circulation, 116, 1137, 10.1161/CIRCULATIONAHA.107.707877
Moss, 2005, Safety and efficacy of flecainide in subjects with Long QT-3 syndrome (DeltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial, Ann Noninvasive Electrocardiol, 10, 59, 10.1111/j.1542-474X.2005.00077.x
Coumel, 1978, Catecholaminergic-induced severe ventricular arrhythmias with Adams-Stokes syndrome in children: report of four cases, Br Heart J, 40, 28
Leenhardt, 1995, Catecholaminergic polymorphic ventricular tachycardia in children, Circulation, 91, 1512, 10.1161/01.CIR.91.5.1512
Priori, 2002, Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia, Circulation, 106, 69, 10.1161/01.CIR.0000020013.73106.D8
Priori, 2001, Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia, Circulation, 103, 196, 10.1161/01.CIR.103.2.196
Lahat, 2001, A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel, Am J Hum Genet, 69, 1378, 10.1086/324565
Bai, 2009, Yield of genetic screening in inherited cardiac channelopathies: how to prioritize access to genetic testing, Circ Arrhythm Electrophysiol, 2, 6, 10.1161/CIRCEP.108.782888
George, 2007, Ryanodine receptors and ventricular arrhythmias: emerging trends in mutations, mechanisms and therapies, J Mol Cell Cardiol, 42, 34, 10.1016/j.yjmcc.2006.08.115
Raffaele di Barletta, 2006, Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia, Circulation, 114, 1012, 10.1161/CIRCULATIONAHA.106.623793
Tester, 2007, A mechanism for sudden infant death syndrome (SIDS): stress-induced leak via ryanodine receptors, Heart Rhythm, 4, 733, 10.1016/j.hrthm.2007.02.026
Tristani-Firouzi, 2002, Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome), J Clin Invest, 110, 381, 10.1172/JCI15183
Mohler, 2004, A cardiac arrhythmia syndrome caused by loss of ankyrin-B function, Proc Natl Acad Sci U S A, 101, 9137, 10.1073/pnas.0402546101
Brugada, 1992, Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome, J Am Coll Cardiol, 20, 1391, 10.1016/0735-1097(92)90253-J
Fowler, 2009, Clinical Spectrum of patients with a Brugada ECG, Curr Opin Cardiol, 24, 74, 10.1097/HCO.0b013e32831cb920
Gehi, 2006, Risk stratification of individuals with the Brugada electrocardiogram: a meta-analysis, J Cardiovasc Electrophysiol, 17, 577, 10.1111/j.1540-8167.2006.00455.x
Priori, 2002, Natural history of Brugada syndrome: insights for risk stratification and management, Circulation, 105, 1342, 10.1161/hc1102.105288
Paul, 2007, Role of programmed ventricular stimulation in patients with Brugada syndrome—a meta-analysis of worldwide published data, Eur Heart J, 28, 2126, 10.1093/eurheartj/ehm116
Probst, 2010, Long-term prognosis of patients diagnosed with Brugada syndrome: results from the FINGER Brugada syndrome registry, Circulation, 121, 635, 10.1161/CIRCULATIONAHA.109.887026
Brugada, 2003, Natural history of Brugada syndrome: the prognostic value of programmed electrical stimulation of the heart, J Cardiovasc Electrophysiol, 14, 455, 10.1046/j.1540-8167.2003.02517.x
Viskin, 2009, Empiric quinidine therapy for asymptomatic Brugada syndrome: time for a prospective registry, Heart Rhythm, 6, 401, 10.1016/j.hrthm.2008.11.030
Kapplinger, 2010, An international compendium of mutation in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing, Heart Rhythm, 1, 33, 10.1016/j.hrthm.2009.09.069
Smits, 2002, Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non SCN5A related patients, J Am Coll Cardiol, 40, 350, 10.1016/S0735-1097(02)01962-9
Antzelevitch, 2007, Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death, Circulation, 115, 442, 10.1161/CIRCULATIONAHA.106.668392
Meregalli, 2009, Type of SCN5A mutation determines clinical severity and degree of conduction slowing in loss-of-function sodium channelopathies, Heart Rhythm, 6, 341, 10.1016/j.hrthm.2008.11.009
Postema, 2009, Drugs and Brugada syndrome patients: review of the literature, recommendations and an up-to-date website, Heart Rhythm, 6, 1335, 10.1016/j.hrthm.2009.07.002
Probst, 2003, Haploinsufficiency in combination with aging causes SCN5A-linked hereditary Lenegre disease, J Am Coll Cardiol, 41, 643, 10.1016/S0735-1097(02)02864-4
Brink, 1977, Progressive familial heart block—two types, S Afr Med J, 52, 53
Postema, 2009, Founder mutations in the Netherlands: SCN5a 1795insD, the first described arrhythmia overlap syndrome and one of the largest and best characterised families worldwide, Neth Heart J, 17, 422, 10.1007/BF03086296
Benson, 2003, Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A), J Clin Invest, 112, 1019, 10.1172/JCI200318062
Schott, 1998, Congenital heart disease caused by mutations in the transcription factor NKX2-5, Science, 281, 108, 10.1126/science.281.5373.108
Paul, 2009, Genes causing inherited forms of cardiomyopathies, Herz, 34, 98, 10.1007/s00059-009-3215-8
Bezzina, 2003, Compound heterozygosity for mutations (W156X and R225W) in SCN5A associated with severe cardiac conduction disturbances and degenerative changes in the conduction system, Circ Res, 92, 159, 10.1161/01.RES.0000052672.97759.36
Neu, 2010, A homozygous SCN5A mutation in a severe, recessive type of cardiac conduction disease, Hum Mutat, 31, E1609, 10.1002/humu.21302
Schott, 1999, Cardiac conduction defects associate with mutations in SCN5A, Nat Genet, 23, 20, 10.1038/12618
Tan, 2001, A sodium-channel mutation causes isolated cardiac conduction disease, Nature, 409, 1043, 10.1038/35059090
Watanabe, 2008, Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans, J Clin Invest, 118, 2260
Kruse, 2009, Impaired endocytosis of the ion channel TRPM4 is associated with human progressive familial heart block type I, J Clin Invest, 119, 2737, 10.1172/JCI38292
Liu, 2010, Gain-of-function mutations in TRPM4 cause autosomal dominant isolated cardiac conduction disease, Circ Cardiovasc Genet, 3, 374, 10.1161/CIRCGENETICS.109.930867
Schulze-Bahr, 2001, A mutation in the cardiac pacemaker channel gene hHCN4 is linked to human sinus node disease, Am J Hum Genet, 69, 183
Milanesi, 2006, Familial sinus bradycardia associated with a mutation in the cardiac pacemaker channel, N Engl J Med, 354, 151, 10.1056/NEJMoa052475
Garg, 2003, GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5, Nature, 424, 443, 10.1038/nature01827
Spaendonck-Zwarts, 2010, Desmin-related myopathy: a review and meta-analysis, Clin Genet
Perrot, 2009, Identification of mutational hot spots in LMNA encoding lamin A/C in patients with familial dilated cardiomyopathy, Basic Res Cardiol, 104, 90, 10.1007/s00395-008-0748-6
van Tintelen, 2007, High yield of LMNA mutations in patients with dilated cardiomyopathy and/or conduction disease referred to cardiogenetics outpatient clinics, Am Heart J, 154, 1130, 10.1016/j.ahj.2007.07.038
McNair, 2004, SCN5A mutation associated with dilated cardiomyopathy, conduction disorder, and arrhythmia, Circulation, 110, 2163, 10.1161/01.CIR.0000144458.58660.BB
Hesse, 2007, Dilated cardiomyopathy is associated with reduced expression of the cardiac sodium channel Scn5a, Cardiovasc Res, 75, 498, 10.1016/j.cardiores.2007.04.009
Olson, 2005, Sodium channel mutations and susceptibility to heart failure and atrial fibrillation, Jama, 293, 447, 10.1001/jama.293.4.447
Shi, 2008, The cardiac sodium channel mutation delQKP 1507-1509 is associated with the expanding phenotypic spectrum of LQT3, conduction disorder, dilated cardiomyopathy, and high incidence of youth sudden death, Europace, 10, 1329, 10.1093/europace/eun202
Ackerman, 2004, Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: implications for arrhythmogenic susceptibility and Brugada/long QT syndrome genetic testing, Heart Rhythm, 1, 600, 10.1016/j.hrthm.2004.07.013
Epstein, 2008, ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: executive summary, Heart Rhythm, 5, 934, 10.1016/j.hrthm.2008.04.015
Gussak, 2000, Idiopathic short QT interval: a new clinical syndrome?, Cardiology, 94, 99, 10.1159/000047299
Gaita, 2003, Short QT syndrome: a familial cause of sudden death, Circulation, 108, 965, 10.1161/01.CIR.0000085071.28695.C4
Rhodes, 2008, Cardiac potassium channel dysfunction in sudden infant death syndrome, J Mol Cell Cardiol, 44, 571, 10.1016/j.yjmcc.2007.11.015
Anttonen, 2007, Prevalence and prognostic significance of short QT-interval in a middle-aged Finnish population, Circulation, 116, 714, 10.1161/CIRCULATIONAHA.106.676551
Funada, 2008, Assessment of QT-intervals and prevalence of Short QT syndrome in Japan, Clin Cardiol, 31, 270, 10.1002/clc.20208
Mason, 2007, Electrocardiographic reference ranges derived from 79,743 ambulatory subjects, J Electrocardiol, 40, 228, 10.1016/j.jelectrocard.2006.09.003
Kobza, 2009, Prevalence of long and short QT in a young population of 41,767 predominantly male Swiss conscripts, Heart Rhythm, 6, 652, 10.1016/j.hrthm.2009.01.009
Gollob, 2011, The short QT syndrome: proposed diagnostic criteria, J Am Coll Cardiol, 57, 802, 10.1016/j.jacc.2010.09.048
Schimpf, 2003, Congenital Short QT syndrome and implantable cardioverter defibrillator treatment: inherent risk for inappropriate shock delivery, J Cardiovasc Electrophysiol, 14, 1273, 10.1046/j.1540-8167.2003.03278.x
Viskin, 2004, Is idiopathic ventricular fibrillation a short QT syndrome?, Heart Rhythm, 1, 587, 10.1016/j.hrthm.2004.07.010
Wolpert, 2005, Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG, J Cardiovasc Electrophysiol, 16, 54, 10.1046/j.1540-8167.2005.04470.x
Gaita, 2004, Short QT syndrome: pharmacological treatment, J Am Coll Cardiol, 43, 1494, 10.1016/j.jacc.2004.02.034
Brugada, 2004, Sudden death associated with short-QT syndrome linked to mutations in HERG, Circulation, 109, 30, 10.1161/01.CIR.0000109482.92774.3A
Cordeiro, 2005, Modulation of Ikr inactivation by mutation N588K in KCNH2: a link to arrhythmogenesis in short QT syndrome, Cardiovasc Res, 67, 498, 10.1016/j.cardiores.2005.02.018
Bellocq, 2004, Mutation in the KCNQ1 gene leading to the short QT-interval syndrome, Circulation, 109, 2394, 10.1161/01.CIR.0000130409.72142.FE
Hong, 2005, De novo KCNQ1 mutation responsible for atrial fibrillation and short QT syndrome in utero, Cardiovasc Res, 68, 433, 10.1016/j.cardiores.2005.06.023
Priori, 2005, A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene, Circ Res, 96, 800, 10.1161/01.RES.0000162101.76263.8c
Hong, 2005, Short QT syndrome et atrial fibrillation caused by mutation in KCNH2, J Cardiovas Electrophysiol, 16, 394, 10.1046/j.1540-8167.2005.40621.x
Antzelevitch, 2007, Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT-intervals, and sudden cardiac death, Circulation, 115, 442, 10.1161/CIRCULATIONAHA.106.668392
Lubitz, 2010, Association between familial atrial fibrillation and risk of new-onset atrial fibrillation, Jama, 304, 2263, 10.1001/jama.2010.1690
Arnar, 2006, Familial aggregation of atrial fibrillation in Iceland, Eur Heart J, 27, 708, 10.1093/eurheartj/ehi727
Chen, 2003, Kcnq1 gain-of-function mutation in familial atrial fibrillation, Science, 299, 251, 10.1126/science.1077771
Das, 2009, Mutation in the s3 segment of kcnq1 results in familial lone atrial fibrillation, Heart Rhythm, 6, 1146, 10.1016/j.hrthm.2009.04.015
Xia, 2005, A kir2.1 gain-of-function mutation underlies familial atrial fibrillation, Biochem Biophys Res Commun, 332, 1012, 10.1016/j.bbrc.2005.05.054
Yang, 2004, Identification of a kcne2 gain-of-function mutation in patients with familial atrial fibrillation, Am J Hum Genet, 75, 899, 10.1086/425342
Makiyama, 2008, A novel scn5a gain-of-function mutation m1875t associated with familial atrial fibrillation, J Am Coll Cardiol, 52, 1326, 10.1016/j.jacc.2008.07.013
Olson, 2006, Kv1.5 channelopathy due to kcna5 loss-of-function mutation causes human atrial fibrillation, Hum Mol Genet, 15, 2185, 10.1093/hmg/ddl143
Hodgson-Zingman, 2008, Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation, N Engl J Med, 359, 158, 10.1056/NEJMoa0706300
Gollob, 2006, Somatic mutations in the connexin 40 gene (gja5) in atrial fibrillation, N Engl J Med, 354, 2677, 10.1056/NEJMoa052800
Gudbjartsson, 2007, Variants conferring risk of atrial fibrillation on chromosome 4q25, Nature, 448, 353, 10.1038/nature06007
Ellinor, 2010, Common variants in kcnn3 are associated with lone atrial fibrillation, Nat Genet, 42, 240, 10.1038/ng.537
Benjamin, 2009, Variants in zfhx3 are associated with atrial fibrillation in individuals of European ancestry, Nat Genet, 41, 879, 10.1038/ng.416
Gudbjartsson, 2009, A sequence variant in zfhx3 on 16q22 associates with atrial fibrillation and ischemic stroke, Nat Genet, 41, 876, 10.1038/ng.417
Maron, 2003, A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines, J Am Coll Cardiol, 42, 1687, 10.1016/S0735-1097(03)00941-0
Watkins, 1992, Sporadic hypertrophic cardiomyopathy due to de novo myosin mutations, J Clin Invest, 90, 1666, 10.1172/JCI116038
Maron, 2007, Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy, Jama, 298, 405, 10.1001/jama.298.4.405
Thierfelder, 1994, Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere, Cell, 77, 701, 10.1016/0092-8674(94)90054-X
Richard, 2003, Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy, Circulation, 107, 2227, 10.1161/01.CIR.0000066323.15244.54
Jääskeläinen, 2004, Genetics of hypertrophic cardiomyopathy in eastern Finland: few founder mutations with benign or intermediary phenotypes, Ann Med, 36, 23, 10.1080/07853890310017161
Geier, 2008, Beyond the sarcomere: CSRP3 mutations cause hypertrophic cardiomyopathy, Hum Mol Genet, 17, 2753, 10.1093/hmg/ddn160
Chiu, 2010, Mutations in a-actinin-2 cause hypertrophic cardiomyopathy: a genome-wide analysis, J Am Coll Cardiol, 55, 1127, 10.1016/j.jacc.2009.11.016
Niimura, 1998, Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy, N Engl J Med, 338, 1248, 10.1056/NEJM199804303381802
Watkins, 1995, Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy, N Engl J Med, 332, 1058, 10.1056/NEJM199504203321603
Van Driest, 2005, Yield of genetic testing in hypertrophic cardiomyopathy, Mayo Clin Proc, 80, 739, 10.4065/80.6.739
Andersen, 2009, Diagnostic yield, interpretation, and clinical utility of mutation screening of sarcomere encoding genes in Danish hypertrophic cardiomyopathy patients and relatives, Hum Mutat, 30, 363, 10.1002/humu.20862
Girolami, 2010, Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations, J Am Coll Cardiol, 55, 1444, 10.1016/j.jacc.2009.11.062
Ingles, 2005, Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling, J Med Genet, 42, e59, 10.1136/jmg.2005.033886
Wordsworth, 2010, DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model, Eur Heart J, 31, 926, 10.1093/eurheartj/ehq067
Elliott, 2000, Sudden death in hypertrophic cardiomyopathy: identification of high risk patients, J Am Coll Cardiol, 36, 2212, 10.1016/S0735-1097(00)01003-2
Olivotto, 2008, Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy, Mayo Clin Proc, 83, 630, 10.4065/83.6.630
Force, 2010, Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute, Circulation, 122, 1130, 10.1161/CIRCULATIONAHA.110.950089
Abozguia, 2010, The metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy, Circulation, 122, 1562, 10.1161/CIRCULATIONAHA.109.934059
Penicka, 2009, The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study, J Mol Diagn, 11, 35, 10.2353/jmoldx.2009.080082
Semsarian, 2002, The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model, J Clin Invest, 109, 1013, 10.1172/JCI200214677
Teekakirikul, 2010, Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-beta, J Clin Invest, 120, 3520, 10.1172/JCI42028
Basso, 1999, Cardiovascular causes of sudden death in young individuals including athletes, Cardiol Rev, 7, 127, 10.1097/00045415-199905000-00009
Tabib, 2003, Circumstances of death and gross and microscopic observations in a series of 200 cases of sudden death associated with arrhythmogenic right ventricular cardiomyopathy and/or dysplasia, Circulation, 108, 3000, 10.1161/01.CIR.0000108396.65446.21
Sen-Chowdhry, 2008, Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity, J Am Coll Cardiol, 52, 2175, 10.1016/j.jacc.2008.09.019
Sen-Chowdhry, 2007, Clinical and genetic characterization of families with arrhythmogenic right ventricular dysplasia/cardiomyopathy provides novel insights into patterns of disease expression, Circulation, 115, 1710, 10.1161/CIRCULATIONAHA.106.660241
Marcus, 2010, Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria, Circulation, 121, 1533, 10.1161/CIRCULATIONAHA.108.840827
Towbin, 2008, Arrhythmogenic right ventricular cardiomyopathy: a paradigm of overlapping disorders, Ann Noninvasive Electrocardiol, 13, 325, 10.1111/j.1542-474X.2008.00241.x
Sen-Chowdhry, 2010, Arrhythmogenic cardiomyopathy: etiology, diagnosis, and treatment, Annu Rev Med, 61, 233, 10.1146/annurev.med.052208.130419
Dalal, 2005, Arrhythmogenic right ventricular dysplasia: a United States experience, Circulation, 112, 3823, 10.1161/CIRCULATIONAHA.105.542266
Peters, 2004, Prevalence of right ventricular dysplasia-cardiomyopathy in a non-referral hospital, Int J Cardiol, 97, 499, 10.1016/j.ijcard.2003.10.037
Sen-Chowdhry, 2005, Genetics of right ventricular cardiomyopathy, J Cardiovasc Electrophysiol, 16, 927, 10.1111/j.1540-8167.2005.40842.x
Dalal, 2006, Penetrance of mutations in plakophilin-2 among families with arrhythmogenic right ventricular dysplasia/cardiomyopathy, J Am Coll Cardiol, 48, 1416, 10.1016/j.jacc.2006.06.045
Awad, 2008, Mechanisms of disease: molecular genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy, Nat Clin Pract Cardiovasc Med, 5, 258, 10.1038/ncpcardio1182
Awad, 2006, Recessive arrhythmogenic right ventricular dysplasia due to novel cryptic splice mutation in PKP2, Hum Mutat, 27, 1157, 10.1002/humu.9461
McKoy, 2000, Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease), Lancet, 355, 2119, 10.1016/S0140-6736(00)02379-5
Norgett, 2000, Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma, Hum Mol Genet, 9, 2761, 10.1093/hmg/9.18.2761
Protonotarios, 2004, Naxos disease and Carvajal syndrome: cardiocutaneous disorders that highlight the pathogenesis and broaden the spectrum of arrhythmogenic right ventricular cardiomyopathy, Cardiovasc Pathol, 13, 185, 10.1016/j.carpath.2004.03.609
Simpson, 2009, Homozygous mutation of desmocollin-2 in arrhythmogenic right ventricular cardiomyopathy with mild palmoplantar keratoderma and woolly hair, Cardiology, 113, 28, 10.1159/000165696
Xu, 2010, Compound and digenic heterozygosity contributes to arrhythmogenic right ventricular cardiomyopathy, J Am Coll Cardiol, 55, 587, 10.1016/j.jacc.2009.11.020
Rampazzo, 2002, Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy, Am J Hum Genet, 71, 1200, 10.1086/344208
Gerull, 2004, Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy, Nat Genet, 36, 1162, 10.1038/ng1461
Pilichou, 2006, Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy, Circulation, 113, 1171, 10.1161/CIRCULATIONAHA.105.583674
Syrris, 2006, Arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in the desmosomal gene desmocollin-2, Am J Hum Genet, 79, 978, 10.1086/509122
Asimaki, 2007, A novel dominant mutation in plakoglobin causes arrhythmogenic right ventricular cardiomyopathy, Am J Hum Genet, 81, 964, 10.1086/521633
Awad, 2006, DSG2 mutations contribute to arrhythmogenic right ventricular dysplasia/cardiomyopathy, Am J Hum Genet, 79, 136, 10.1086/504393
Merner, 2008, Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene, Am J Hum Genet, 82, 809, 10.1016/j.ajhg.2008.01.010
Beffagna, 2005, Regulatory mutations in transforming growth factor-beta3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1, Cardiovasc Res, 65, 366, 10.1016/j.cardiores.2004.10.005
Tiso, 2001, Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2), Hum Mol Genet, 10, 189, 10.1093/hmg/10.3.189
Corrado, 2006, Arrhythmogenic right ventricular cardiomyopathy/dysplasia: clinical impact of molecular genetic studies, Circulation, 113, 1634, 10.1161/CIRCULATIONAHA.105.616490
Sen-Chowdhry, 2007, Role of genetic analysis in the management of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy, J Am Coll Cardiol, 50, 1813, 10.1016/j.jacc.2007.08.008
van Tintelen, 2006, Plakophilin-2 mutations are the major determinant of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy, Circulation, 113, 1650, 10.1161/CIRCULATIONAHA.105.609719
Christensen, 2010, Missense variants in plakophilin-2 in arrhythmogenic right ventricular cardiomyopathy patients—disease-causing or innocent bystanders?, Cardiology, 115, 148, 10.1159/000263456
Posch, 2008, Variations in DSG2: V56M, V158G and V920G are not pathogenic for arrhythmogenic right ventricular dysplasia/cardiomyopathy, Nat Clin Pract Cardiovasc Med, 5, E1, 10.1038/ncpcardio1434
Posch, 2008, A missense variant in desmoglein-2 predisposes to dilated cardiomyopathy, Mol Genet Metab, 95, 74, 10.1016/j.ymgme.2008.06.005
Bauce, 2010, Multiple mutations in desmosomal proteins encoding genes in arrhythmogenic right ventricular cardiomyopathy/dysplasia, Heart Rhythm, 7, 22, 10.1016/j.hrthm.2009.09.070
Bauce, 2005, Clinical profile of four families with arrhythmogenic right ventricular cardiomyopathy caused by dominant desmoplakin mutations, Eur Heart J, 26, 1666, 10.1093/eurheartj/ehi341
Dalal, 2006, Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2, Circulation, 113, 1641, 10.1161/CIRCULATIONAHA.105.568642
Sen-Chowdhry, 2010, Mutational heterogeneity, modifier genes, and environmental influences contribute to phenotypic diversity of arrhythmogenic cardiomyopathy, Circ Cardiovasc Genet, 3, 323, 10.1161/CIRCGENETICS.109.935262
Kirchhof, 2006, Age- and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice, Circulation, 114, 1799, 10.1161/CIRCULATIONAHA.106.624502
Michels, 1992, The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy, N Engl J Med, 326, 77, 10.1056/NEJM199201093260201
Baig, 1998, Familial dilated cardiomyopathy: cardiac abnormalities are common in asymptomatic relatives and may represent early disease, J Am Coll Cardiol, 31, 195, 10.1016/S0735-1097(97)00433-6
Grunig, 1998, Frequency and phenotypes of familial dilated cardiomyopathy, J Am Coll Cardiol, 31, 186, 10.1016/S0735-1097(97)00434-8
Hershberger, 2009, Genetic evaluation of cardiomyopathy—a Heart Failure Society of America practice guideline, J Card Fail, 15, 83, 10.1016/j.cardfail.2009.01.006
Judge, 2008, Genetic evaluation of familial cardiomyopathy, J Cardiovasc Trans Res, 1, 144, 10.1007/s12265-008-9025-1
Hershberger, 2010, Clinical and genetic issues in dilated cardiomyopathy: a review for genetics professionals, Genet Med, 12, 655, 10.1097/GIM.0b013e3181f2481f
Spaendonck-Zwarts, 2010, Desmin-related myopathy: a review and meta-analysis, Clin Genet
Engberding, 2007, Isolated noncompaction of the left ventricular myocardium: a review of the literature two decades after the initial case description, Clin Res Cardiol, 96, 481, 10.1007/s00392-007-0528-6
Pignatelli, 2003, Clinical characterization of left ventricular noncompaction in children, Circulation, 108, 2672, 10.1161/01.CIR.0000100664.10777.B8
Scaglia, 2004, Clinical spectrum, morbidity, and mortality in 113 pediatric patients with mitochondrial disease, Pediatrics, 114, 925, 10.1542/peds.2004-0718
Towbin, 2010, Left ventricular noncompaction: a new form of heart failure, Heart Fail Clin, 6, 453, 10.1016/j.hfc.2010.06.005
Klaassen, 2008, Mutations in sarcomere protein genes in left ventricular noncompaction, Circulation, 117, 2893, 10.1161/CIRCULATIONAHA.107.746164
Vatta, 2003, Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction, J Am Coll Cardiol, 42, 2014, 10.1016/j.jacc.2003.10.021
Ichida, 2001, Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome, Circulation, 103, 1256, 10.1161/01.CIR.103.9.1256
Shan, 2008, SCN5A variants in Japanese patients with left ventricular noncompaction and arrhythmia, Mol Genet Metab, 93, 468, 10.1016/j.ymgme.2007.10.009
Hoedemaekers, 2010, The importance of genetic counseling, DNA diagnostics, and cardiologic family screening in left ventricular noncompaction cardiomyopathy, Circ Cardiovasc Genet, 3, 232, 10.1161/CIRCGENETICS.109.903898
Bleyl, 1997, Neonatal lethal noncompaction of the ventricular myocardium is allelic with Barth syndrome, Am J Hum Genet, 61, 868, 10.1086/514879
Finsterer, 2008, Primary myopathies and the heart, Scand Cardiovasc J, 42, 9, 10.1080/14017430701854953
Tang, 2010, Left ventricular noncompaction is associated with mutations in the mitochondrial genome, Mitochondrion, 10, 350, 10.1016/j.mito.2010.02.003
Jacquier, 2010, Measurement of trabeculated left ventricular mass using cardiac magnetic resonance imaging in the diagnosis of left ventricular non-compaction, Eur Heart J, 31, 1098, 10.1093/eurheartj/ehp595
Eidem, 2009, Noninvasive evaluation of left ventricular noncompaction: what's new in 2009?, Pediatr Cardiol, 30, 682, 10.1007/s00246-008-9372-3
Sen-Chowdhry, 2010, Genetics of restrictive cardiomyopathy, Heart Fail Clin, 6, 179, 10.1016/j.hfc.2009.11.005
Stollberger, 2007, Extracardiac medical and neuromuscular implications in restrictive cardiomyopathy, Clin Cardiol, 30, 375, 10.1002/clc.20005
Meredith, 2004, Mutations in the slow skeletal muscle fiber myosin heavy chain gene (MYH7) cause Laing early-onset distal myopathy (MPD1), Am J Hum Genet, 75, 703, 10.1086/424760
Kaski, 2008, Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genes, Heart, 94, 1478, 10.1136/hrt.2007.134684
Kubo, 2007, Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype, J Am Coll Cardiol, 49, 2419, 10.1016/j.jacc.2007.02.061
Falk, 2005, Diagnosis and management of the cardiac amyloidoses, Circulation, 112, 2047, 10.1161/CIRCULATIONAHA.104.489187
Jacobson, 1997, Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans, N Engl J Med, 336, 466, 10.1056/NEJM199702133360703
Tartaglia, 2005, Noonan syndrome and related disorders: genetics and pathogenesis, Annu Rev Genomics Hum Genet, 6, 45, 10.1146/annurev.genom.6.080604.162305
Tartaglia, 2001, Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome, Nat Genet, 29, 465, 10.1038/ng772
Tartaglia, 2002, PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity, Am J Hum Genet, 70, 1555, 10.1086/340847
Croonen, 2008, Electrocardiography in Noonan syndrome PTPN11 gene mutation–phenotype characterization, Am J Med Genet A, 146, 350, 10.1002/ajmg.a.32140
Pandit, 2007, Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy, Nat Genet, 39, 1007, 10.1038/ng2073
van der Werf, 2010, Diagnostic yield in sudden unexplained death and aborted vcardiac arrest in the young: the experience of a tertiary referral center in The Netherlands, Heart Rhythm, 7, 1383, 10.1016/j.hrthm.2010.05.036
Folke, 2010, Differences between out-of-hospital cardiac arrest in residential and public locations and implications for public-access defibrillation, Circulation, 122, 623, 10.1161/CIRCULATIONAHA.109.924423
Marcus, 2010, Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria, Circulation, 121, 1533, 10.1161/CIRCULATIONAHA.108.840827
Vasaiwala, 2009, Prospective study of cardiac sarcoid mimicking arrhythmogenic right ventricular dysplasia, J Cardiovasc Electrophysiol, 20, 479, 10.1111/j.1540-8167.2008.01351.x
Krahn, 2009, Systematic assessment of patients with unexplained cardiac arrest: Cardiac Arrest Survivors With Preserved Ejection Fraction Registry (CASPER), Circulation, 120, 278, 10.1161/CIRCULATIONAHA.109.853143
Haïssaguerre, 2008, Sudden cardiac arrest associated with early repolarization, N Engl J Med, 358, 2016, 10.1056/NEJMoa071968
Alders, 2009, Haplotype Sharing analysis implicates chromosome 7q36 harboring DPP6 in familial idiopathic ventricular fibrillation, Am J Hum Genet, 84, 468, 10.1016/j.ajhg.2009.02.009
Ackerman, 2001, Molecular autopsy of sudden unexplained death in the young, Am J Forensic Med Pathol, 22, 105, 10.1097/00000433-200106000-00001
Doolan, 2004, Causes of sudden cardiac death in young Australians, Med J Aust, 180, 110, 10.5694/j.1326-5377.2004.tb05830.x
Ackerman, 2001, Postmortem molecular analysis of SCN5A defects in sudden infant death syndrome, Jama, 286, 2264, 10.1001/jama.286.18.2264
Van Norstrand, 2007, Molecular and functional characterization of novel glycerol-3-phosphate dehydrogenase 1 like gene (GPD1–L) mutations in sudden infant death syndrome, Circulation, 116, 2253, 10.1161/CIRCULATIONAHA.107.704627
Wang, 2007, Cardiac sodium channel dysfunction in sudden infant death syndrome, Circulation, 115, 368, 10.1161/CIRCULATIONAHA.106.646513
Arnestad, 2007, Prevalence of long-QT syndrome gene variants in sudden infant death syndrome, Circulation, 115, 361, 10.1161/CIRCULATIONAHA.106.658021
Tester, 2004, Targeted mutational analysis of the RyR2-encoded cardiac ryanodine receptor in sudden unexplained death: a molecular autopsy of 49 medical examiner/coroner's cases, Mayo Clin Proc, 79, 1380, 10.4065/79.11.1380
Tester, 2007, Postmortem long QT syndrome genetic testing for sudden unexplained death in the young, J Am Coll Cardiol, 49, 240, 10.1016/j.jacc.2006.10.010
Schwartz, 1998, Prolongation of the QT interval and the sudden infant death syndrome, N Engl J Med, 338, 1709, 10.1056/NEJM199806113382401
Schwartz, 2000, A molecular link between the sudden infant death syndrome and the long-QT syndrome, N Engl J Med, 343, 262, 10.1056/NEJM200007273430405
Tan, 2005, Sudden unexplained death: heritability and diagnostic yield of cardiological and genetic examination in surviving relatives, Circulation, 112, 207, 10.1161/CIRCULATIONAHA.104.522581
Behr, 2003, Cardiological assessment of first-degree relatives in sudden arrhythmic death syndrome, Lancet, 362, 1457, 10.1016/S0140-6736(03)14692-2
Ingles, 2007, Sudden cardiac death in the young: a clinical genetic approach, Intern Med J, 37, 32, 10.1111/j.1445-5994.2006.01241.x
Carturan, 2008, Postmortem genetic testing for conventional autopsy-negative sudden unexplained death: an evaluation of different DNA extraction protocols and the feasibility of mutational analysis from archival paraffin-embedded heart tissue, Am J Clin Pathol, 129, 391, 10.1309/VLA7TT9EQ05FFVN4